MARKET

EARS

EARS

Auris Medical Holding Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.080
+0.070
+2.33%
Closed 16:00 09/18 EDT
OPEN
3.020
PREV CLOSE
3.010
HIGH
3.200
LOW
3.010
VOLUME
324.85K
TURNOVER
--
52 WEEK HIGH
39.40
52 WEEK LOW
2.410
MARKET CAP
74.16M
P/E (TTM)
-0.4399
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EARS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

EARS News

  • Auris clarifies endpoint for Phase 2/3 study of Keyzilen for tinnitus; shares up 3%
  • Seeking Alpha - Article.5d ago
  • Auris Medical Receives FDA And EMA Guidance On Keyzilen Program FDA And EMA Supported Use Of Tinnitus Functional Index Questionnaire As PRimary Efficacy Outcome Measure
  • Benzinga.5d ago
  • Auris Medical Receives FDA and EMA Guidance for Keyzilen® Late-Stage Clinical Development Program
  • GlobeNewswire.5d ago
  • Auris Medical nabs new patent in U.S. and Europe
  • Seeking Alpha - Article.09/11 13:31

More

Industry

Biotechnology & Medical Research
-0.68%
Pharmaceuticals & Medical Research
-0.14%

Hot Stocks

Name
Price
%Change

About EARS

Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The Company operates through subsidiaries in Switzerland, Ireland and the United States.
More

Webull offers Auris Medical Holding Ltd (EARS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.